• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Journal of Advanced Pharmacy Research
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 9 (2025)
Volume Volume 8 (2024)
Volume Volume 7 (2023)
Volume Volume 6 (2022)
Volume Volume 5 (2021)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 4 (2020)
Volume Volume 3 (2019)
Volume Volume 2 (2018)
Volume Volume 1 (2017)
Alzarie, Y., Badary, O., Nofal, S. (2021). Metalloporphyrins: Radioprotector and Radiosensitizer. Journal of Advanced Pharmacy Research, 5(2), 276-284. doi: 10.21608/aprh.2021.55777.1121
Yasmin Alzarie; Osama Badary; Shahira Nofal. "Metalloporphyrins: Radioprotector and Radiosensitizer". Journal of Advanced Pharmacy Research, 5, 2, 2021, 276-284. doi: 10.21608/aprh.2021.55777.1121
Alzarie, Y., Badary, O., Nofal, S. (2021). 'Metalloporphyrins: Radioprotector and Radiosensitizer', Journal of Advanced Pharmacy Research, 5(2), pp. 276-284. doi: 10.21608/aprh.2021.55777.1121
Alzarie, Y., Badary, O., Nofal, S. Metalloporphyrins: Radioprotector and Radiosensitizer. Journal of Advanced Pharmacy Research, 2021; 5(2): 276-284. doi: 10.21608/aprh.2021.55777.1121

Metalloporphyrins: Radioprotector and Radiosensitizer

Article 3, Volume 5, Issue 2, April 2021, Page 276-284  XML PDF (212.57 K)
Document Type: Review Article
DOI: 10.21608/aprh.2021.55777.1121
View on SCiNiTO View on SCiNiTO
Authors
Yasmin Alzarie1, 2; Osama Badary3; Shahira Nofal email 4
1Department of Internal Medicine, Davis Heart & Lung Research Institute, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA.
2National Organization of Drug Control and Research, Cairo, Egypt.
3Department of Pharmacology, Faculty of Pharmacy, British University in Egypt.
4Department of Pharmacology and Toxicology, College of Pharmacy, Helwan University, Cairo, Egypt.
Abstract
Cancer has become the leading cause of human death in the world, due to its uncontrolled and rapid proliferation properties. Radio and chemotherapy are used in the treatment of almost all types of cancer. They mostly act by increasing the production of reactive oxygen specious (ROS) and free radicals. ROS levels are believed to be higher in cancer cells compared to their normal counterparts this is suggested to be related to cancer cell growth, angiogenesis, and metastasis. Although the cure rate for many types of cancer would be increased by radiation dose escalation, balancing the potential for cure against the risk for normal tissue injury is a complex endeavor. Because normal tissue toxicity during radiotherapy and pathological conditions that include overproduction of unstable oxygen species, efforts are ongoing to develop new radioprotective drugs. Antioxidants is an example of co treatment which has potential to protect normal tissues against radiation-induced damage with increasing IR-induced damage for cancer. Since the discovery of superoxide dimutases (SODs), a family of metalloproteins, it has become clear that these enzymes provide an essential defense against the superoxide radical. Application of native SOD has been limited due to short half-lives, lack of cellular uptake and hypersensitivity. Metal-containing SOD mimetics have now emerged as being especially promising, they have been used for treatment of different kinds of diseases, as cancer. It is believed to protect cells from radiation damage by removing free radicals produced by irradiation. The objective of this review is to summarize the most current metalloporphyrin as an example of SODm in treatment of cancer and in combination with other radio and chemotherapy.
Keywords
SOD; Metalloporphyrin; Cancer; ROS
Main Subjects
Section D: Clinical Pharmacy & Pharmacology
Statistics
Article View: 315
PDF Download: 483
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.